\n\nMethods: Seventy-two healthy male subjects with LDL cholesterol <190mg/dL participated in the study. Twenty four subjects were treated with ezetimibe (10mg), simvastatin (40mg) or their combination, respectively, for two weeks. Blood was drawn before and after the 2-week\n\nResults: Eleven CC homozygous carriers of the gene were found (15 %). There were no differences in cholesterol synthesis OF absorption between the CC homozygotes and the

G allele-carriers, as measured by the ratios to cholesterol of serum lathosterol, desmosterol and cholestenol (synthesis markers) and cholestanol, sitosterol and campesterol (absorption markers). Ezetimibe had a significantly more potent effect in blocking cholesterol absorption in the CC homozygotes compared to the G-carriers (P=0.002).\n\nConclusions: The G/C NVP-LBH589 (G952G) polymorphism of the SREBP-1 LY333531 in vivo gene is not associated with cholesterol synthesis or absorption in a German male population. The CC homozygotes have a significantly increased response to the effects of ezetimibe on cholesterol absorption compared to the G allele-carriers, suggesting that

SREBP-I may be implicated in ezetimibe’s mechanism of action. treatment period.”
“The hypothetical relationship between circadian rhythms alterations and depression has prompted studies that examine the resultant effects of various antidepressants. Electroconvulsive therapy (ECT) exerts significant antidepressant effects that have been modelled in the laboratory via the use of electroconvulsive shock (ECS) in rats. However, data on the effects of ECT or ECS vis-A-vis the circadian rhythms remain Galardin cost scarce. Thus, we report here the effects of acute and chronic ECS administration on the temperature and motor activity circadian rhythms of rats. The motor activity and core body temperature of rats were continuously recorded to determine the circadian rhythms. We carried out three experiments. In the first, we analyzed the effects of acute ECS on both the phase and period

when applied at different times of the subjective day. In the second and third experiments ECS was nearly daily applied to rats for 3 weeks: respectively, under dim red light, which allows a robust free-running circadian rhythm; and under light-dark cycles of 22 h (T22), a setting that implies dissociation in the circadian system. Acute ECS does not modify the phase or the period of circadian rhythms. Chronic administration of ECS produces an increase in motor activity and temperature, a decrease in the amplitude of circadian rhythms, although the period of the free-running rhythm remains unaffected. In conclusion, while chronic ECS does alter the overt rhythms of motor activity and temperature, it does not modify the functioning of the circadian pacemaker. (C) 2008 Elsevier B.V.